More than 97.3 per cent of COVID-19 patients who received 'Sotrovimab' in the UAE recovered significantly within 5-7 days.
The two-week treatment results for the new anti-viral drug have been announced by the Ministry of Health and Prevention, in collaboration with the Department of Health - Abu Dhabi and Dubai Health Authority.
Between June 16-29, Sotrovimab was administered to 658 patients, 46 per cent of whom are citizens and 54 per cent of whom are residents.
About 59 per cent of the patients are aged 50 or above.
The UAE was one of the first countries in the world to receive a shipment of Sotrovimab in mid-June.
It is used for treating severe COVID-19 cases in adults, pregnant women and children aged 12 and above who are at risk of progressing to severe symptoms and meet other relevant criteria.
Sotrovimab, produced by GSK, has been approved for emergency use by the US Food and Drug Administration and the Ministry of Health and Prevention.
— مكتب أبوظبي الإعلامي (@ADMediaOffice) June 30, 2021
Read more: https://t.co/JaVL0ix57J
'Abu Dhabi Declaration' adopted as UN crime congress opens
Qatar Emir offers condolences to H.H. Sheikh Mohammed
UAE President meets senior Uzbekistan official
Sheikh Abdullah hosts UNGA reception in New York
UAE expresses solidarity with DR Congo over plane crash
Sheikh Abdullah holds series of meetings at UN General Assembly
UAE allocates $10 million to fight Ebola outbreak in Africa
Dubai event prepares more than 10 million meals for Gaza
